This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
TEVA to Pay $225 Million to Settle Price-Fixing Charges (Revised)
by Zacks Equity Research
TEVA agrees to pay a fine of $225 million over five years per a DPA. Out of this amount, $22.5 million will be due each year from 2024 through 2027 and $135 million will become due in 2028.
TEVA to Pay $250 Million to Settle Price-Fixing Charges
by Zacks Equity Research
TEVA agrees to pay a fine of $225 million over five years per a DPA. Out of this amount, $22.5 million will be due each year from 2024 through 2027 and $135 million will become due in 2028.
Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Dr. Reddy's Laboratories and Teva Pharmaceutical
by Zacks Equity Research
Amphastar Pharmaceuticals, Dr. Reddy's Laboratories and Teva Pharmaceutical are part of the Zacks Industry Outlook article.
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
by Sundeep Ganoria
The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to AMPH, RDY and TEVA.
TEVA Q2 Earnings & Sales Top as Austedo Outperforms, Stock Up
by Zacks Equity Research
TEVA's second-quarter results were strong as it beat estimates for earnings as well sales.
Exelixis (EXEL) Q2 Earnings Top, Cabometyx Drives Growth
by Zacks Equity Research
Exelixis (EXEL) beats second-quarter 2023 earnings and sales estimates as Cabometyx drives growth in approved indications.
Here's What Key Metrics Tell Us About Teva Pharmaceutical Industries Ltd. (TEVA) Q2 Earnings
by Zacks Equity Research
The headline numbers for Teva Pharmaceutical Industries Ltd. (TEVA) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks Industry Outlook Highlights Amphastar, Dr. Reddy's and Teva Pharmaceutical
by Zacks Equity Research
Amphastar, Dr. Reddy's and Teva Pharmaceutical have been highlighted in this Industry Outlook article.
3 Generic Drug Stocks to Watch Amid Macro Headwinds
by Sundeep Ganoria
The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and TEVA.
TEVA Q1 Earnings Miss Estimates, Sales Beat, Stock Declines
by Zacks Equity Research
TEVA reports mixed Q1 results, missing earnings estimates but beating the same for revenues. Stock falls.
Compared to Estimates, Teva Pharmaceutical Industries Ltd. (TEVA) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Teva Pharmaceutical Industries Ltd. (TEVA) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Embecta (EMBC) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Embecta's (EMBC) diabetes care business is expected to have progressed in the fiscal second quarter banking on strong execution of its three strategic pillars.
Charles River (CRL) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Continued global demand for research models and associated services are likely to have driven Charles River's (CRL) Q1 revenues.
CVS Health (CVS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
CVS Health's (CVS) digital capabilities are expected to have driven consumer engagement across all CVS Health businesses in Q1.
GYN Surgical Sales to Aid Hologic (HOLX) in Q2 Earnings
by Zacks Equity Research
Strong performance led by MyoSure and NovaSure is expected to have driven Hologic' s (HOLX) Q2 performance.
Hologic (HOLX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Robust performance from MyoSure and NovaSure along with increasing contributions from the company's laparoscopic portfolio are expected to have contributed to the Hologic's (HOLX) Q2 reveneus.
Henry Schein (HSIC) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Henry Schein's (HSIC) medical business is expected to have gained from improved U.S. patient traffic to physician offices, ultimate care sites and ambulatory surgical centers.
What's in Store for Edwards Lifesciences (EW) in Q1 Earnings?
by Zacks Equity Research
Continued demand for the HemoSphere monitoring platform and Smart Recovery is likely to have contributed to the Edwards Lifesciences' (EW) Q1 growth.
Zimmer Biomet (ZBH) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Zimmer Biomet (ZBH) might have faced an upheaval in business, thanks to the global inflationary situation in terms of mounting labor and raw material costs, severe staffing shortages and supply issues.
What's in Store for Boston Scientific (BSX) in Q1 Earnings?
by Zacks Equity Research
Boston Scientific (BSX) is expected to have registered strong growth in EMEA within structural heart, including TAVR, WATCHMAN, and other interventional cardiology therapies in the first quarter.
What's in Store for Thermo Fisher (TMO) in Q1 Earnings?
by Zacks Equity Research
Thermo Fisher (TMO) is likely to have generated growth in the first quarter, driven by a favorable business mix and new launches.
LabCorp (LH) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Ongoing sales rebound in the base business for both Diagnostics and Drug Development segments is likely to have benefited LabCorp (LH) in Q1.
Alvotech (ALVO) Declines on CRL for Humira's Biosimilar Candidate
by Zacks Equity Research
Alvotech's shares decline as it receives a complete response letter for biosimilar candidate, AVT02, treating autoimmune disorders.
Is Teva Pharmaceutical Industries (TEVA) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
What's in Store for Abbott Laboratories (ABT) in Q1 Earnings?
by Zacks Equity Research
Abbott Laboratories' (ABT) Established Pharmaceuticals Division (EPD) and Diabetes arm are boosting business in recent months.